Personal CFO Solutions LLC Acquires 129 Shares of Illumina, Inc. (NASDAQ:ILMN)

Personal CFO Solutions LLC increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,982 shares of the life sciences company’s stock after buying an additional 129 shares during the period. Personal CFO Solutions LLC’s holdings in Illumina were worth $747,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Steward Partners Investment Advisory LLC increased its stake in Illumina by 1.5% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 3,689 shares of the life sciences company’s stock valued at $746,000 after acquiring an additional 54 shares during the last quarter. Geneos Wealth Management Inc. boosted its holdings in shares of Illumina by 28.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 270 shares of the life sciences company’s stock valued at $94,000 after purchasing an additional 60 shares in the last quarter. Venturi Wealth Management LLC increased its stake in shares of Illumina by 8.7% in the 2nd quarter. Venturi Wealth Management LLC now owns 751 shares of the life sciences company’s stock valued at $141,000 after purchasing an additional 60 shares during the last quarter. ICICI Prudential Asset Management Co Ltd raised its holdings in shares of Illumina by 6.2% during the 2nd quarter. ICICI Prudential Asset Management Co Ltd now owns 1,074 shares of the life sciences company’s stock worth $201,000 after buying an additional 63 shares in the last quarter. Finally, Lido Advisors LLC lifted its position in shares of Illumina by 3.7% during the 2nd quarter. Lido Advisors LLC now owns 1,752 shares of the life sciences company’s stock worth $329,000 after buying an additional 63 shares during the last quarter. 92.17% of the stock is currently owned by institutional investors and hedge funds.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $94.32 on Friday. The company has a market capitalization of $14.98 billion, a PE ratio of -13.25, a P/E/G ratio of 6.66 and a beta of 1.16. The company has a quick ratio of 1.28, a current ratio of 1.69 and a debt-to-equity ratio of 0.25. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $238.55. The firm has a fifty day simple moving average of $124.78 and a 200 day simple moving average of $166.21.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, November 9th. The life sciences company reported $0.33 EPS for the quarter, beating the consensus estimate of $0.13 by $0.20. Illumina had a positive return on equity of 2.13% and a negative net margin of 25.20%. The company had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the prior year, the company earned $0.34 EPS. The firm’s revenue for the quarter was up .4% compared to the same quarter last year. On average, sell-side analysts forecast that Illumina, Inc. will post 0.68 EPS for the current year.

Insider Activity

In related news, SVP Susan H. Tousi sold 500 shares of the stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $167.04, for a total transaction of $83,520.00. Following the transaction, the senior vice president now directly owns 45,524 shares of the company’s stock, valued at $7,604,328.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, SVP Susan H. Tousi sold 500 shares of the business’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $167.04, for a total value of $83,520.00. Following the completion of the sale, the senior vice president now directly owns 45,524 shares of the company’s stock, valued at approximately $7,604,328.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Aimee L. Hoyt sold 315 shares of the stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $112.84, for a total value of $35,544.60. Following the completion of the transaction, the senior vice president now owns 8,314 shares in the company, valued at approximately $938,151.76. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on ILMN shares. Bank of America lowered their target price on Illumina from $230.00 to $210.00 in a research note on Thursday, August 10th. Royal Bank of Canada cut their target price on shares of Illumina from $337.00 to $328.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 8th. Credit Suisse Group lowered their price target on shares of Illumina from $225.00 to $200.00 and set a “neutral” rating for the company in a report on Thursday, August 10th. HSBC dropped their price target on Illumina from $230.00 to $171.00 in a research note on Friday, September 29th. Finally, JPMorgan Chase & Co. reduced their price objective on Illumina from $235.00 to $190.00 and set a “neutral” rating on the stock in a research report on Thursday, August 10th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $194.56.

About Illumina

Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.